Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Achaogen, Inc.AKAO · Entity 158957 | Director | June 05, 2018 | June 07, 2018 |
| Arcutis Biotherapeutics, Inc.ARQT · Entity 4236 | Director | June 05, 2026 | June 10, 2026 |
| CytomX Therapeutics, Inc.CTMX · Entity 5124 | Director | June 17, 2026 | June 22, 2026 |
| IRONWOOD PHARMACEUTICALS INCIRWD · Entity 5213 | Chief Admin Officer & SVP | February 21, 2020 | February 25, 2020 |
| NEOGENOMICS INCNEO · Entity 2096 | Chief Legal Officer | March 01, 2022 | March 04, 2022 |
| Vaxcyte, Inc.PCVX · Entity 1164 | Director | June 15, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Achaogen, Inc.
Report date June 05, 2018 · Filed June 07, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.07 · Expires 2028-06-05 | Direct | 15,000 |
Reported balance
After 2018-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-05 · Grant · Acquired 15,000 · Balance 15,000 F1: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date.
Arcutis Biotherapeutics, Inc.
Report date June 05, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,901 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 5,778 · Balance 27,901 F1: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.23 · Expires 2036-06-05 | Direct | 16,667 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Grant · Acquired 16,667 · Balance 16,667 F2: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.
F2: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.
CytomX Therapeutics, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.96 · Expires 2036-06-16 | Direct | 59,000 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 59,000 · Balance 59,000 F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
IRONWOOD PHARMACEUTICALS INC
Report date February 21, 2020 · Filed February 25, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 265,991 |
Ending reported balance
After 2020-02-21 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2020-02-21 · Sale · Disposed 2,753 · Balance 278,566 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 1, 2016. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 2 · 2020-02-21 · Sale · Disposed 3,410 · Balance 275,156 F3: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2017. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 3 · 2020-02-21 · Sale · Disposed 2,984 · Balance 272,172 F4: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 21, 2018. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 4 · 2020-02-21 · Sale · Disposed 6,181 · Balance 265,991 F5: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 29, 2019. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 1, 2016.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2017.
F4: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 21, 2018.
F5: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 29, 2019.
NEOGENOMICS INC
Report date March 01, 2022 · Filed March 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 147,396 |
Reported balance
After 2022-03-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-03-01 · Grant · Acquired 42,036 · Balance 147,396 F1: On March 1, 2022, Ms. Gilbert was granted 42,036 restricted stock awards. These awards vest ratably over the first four anniversary dates of the grant date. F2: This balance includes 97 shares that were acquired at a price of $19.16 per share pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) during the month ended January 31, 2022. The shares were acquired in transactions exempt from Section 16b-3. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.41 · Expires 2029-03-01 | Direct | 102,623 |
Reported balance
After 2022-03-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-01 · Grant · Acquired 102,623 · Balance 102,623 F4: On March 1, 2022, Ms. Gilbert was granted 102,623 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.21 · Expires 2028-08-17 | Direct | 63,331 |
Reported balance
Holding disclosure · report date 2022-03-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 63,331 F3: On August 17, 2021, Ms. Gilbert was granted 63,331 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 1, 2022, Ms. Gilbert was granted 42,036 restricted stock awards. These awards vest ratably over the first four anniversary dates of the grant date.
F2: This balance includes 97 shares that were acquired at a price of $19.16 per share pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) during the month ended January 31, 2022. The shares were acquired in transactions exempt from Section 16b-3.
F3: On August 17, 2021, Ms. Gilbert was granted 63,331 stock options. These options vest ratably over the first four anniversary dates of the grant date.
F4: On March 1, 2022, Ms. Gilbert was granted 102,623 stock options. These options vest ratably over the first four anniversary dates of the grant date.
Vaxcyte, Inc.
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,481 |
Reported balance
After 2026-06-15 transaction · row 1
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 2,265 · Balance 12,481 F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.56 · Expires 2036-06-15 | Direct | 11,389 |
Reported balance
After 2026-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-15 · Grant · Acquired 11,389 · Balance 11,389 F2: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
F2: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Dermira, Inc.
Report date February 20, 2020 · Filed February 24, 2020
Section 16 reporting ended · disclosed 2020-02-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.05 · Expires 2029-11-10 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-20 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2017 Filed Feb 15, 2017 23:12 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass B Common Stock | 37,385 | $16.75 | $626,198.75 |
DisclosureSEC source: 0001209191-17-011203 · doc4.xml · nonDerivative · entry 2 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. In order to effect the sale, these shares of Class B Common Stock were converted into shares of Class A Common Stock in accordance with the issuer's certificate of incorporation. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 23:12 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass B Common Stock | 37,385 | $3.76 | $140,567.60 |
DisclosureSEC source: 0001209191-17-011203 · doc4.xml · nonDerivative · entry 1 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,385 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 18:08 UTC | Achaogen, Inc. AKAO · Entity 158957 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $14.88 | $0.00 |
DisclosureSEC source: 0001140361-17-001066 · doc1.xml · derivative · entry 1 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-01-04 F1 · derivative.exercise_date: The shares subject to the option vest in 36 successive, equal monthly installments on each monthly anniversary of January 4, 2017, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| November 11, 2016 Filed Nov 15, 2016 22:11 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 14,000 | $3.76 Strike: $3.76 | $52,640.00 |
DisclosureSEC source: 0001209191-16-150218 · doc4.xml · derivative · entry 4 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 14,000 shares Expires 2018-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested upon the earlier of (i) the issuer's achievement of a regulatory milestone and (ii) February 1, 2014. The regulatory milestone was met, so the option was fully vested as of October 24, 2011. Read SEC document |
| November 11, 2016 Filed Nov 15, 2016 22:11 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass B Common Stock | 14,000 | $16.75 | $234,500.00 |
DisclosureSEC source: 0001209191-16-150218 · doc4.xml · nonDerivative · entry 2 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. In order to effect the sale, these shares of Class B Common Stock were converted into shares of Class A Common Stock in accordance with the issuer's certificate of incorporation. Read SEC document |
| November 11, 2016 Filed Nov 15, 2016 22:11 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass B Common Stock | 14,000 | $3.76 | $52,640.00 |
DisclosureSEC source: 0001209191-16-150218 · doc4.xml · nonDerivative · entry 1 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.